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Abstract
Androgens, required for normal development and fertility of males and females, have vital roles in the reproductive
tract, brain, cardiovascular system, smooth muscle and bone. Androgens function via the androgen receptor (AR), a
ligand-dependent transcription factor. To assay and localise AR activity in vivo we generated the transgenic “ARE-
Luc” mouse, expressing a luciferase reporter gene under the control of activated endogenous AR. In vivo imaging of
androgen-mediated luciferase activity revealed several strongly expressing tissues in the male mouse as expected
and also in certain female tissues. In males the testes, prostate, seminal vesicles and bone marrow all showed high
AR activity. In females, strong activity was seen in the ovaries, uterus, omentum tissue and mammary glands. In both
sexes AR expression and activity was also found in salivary glands, the eye (and associated glands), adipose tissue,
spleen and, notably, regions of the brain. Luciferase protein expression was found in the same cell layers as
androgen receptor expression. Additionally, mouse AR expression and activity correlated well with AR expression in
human tissues. The anti-androgen bicalutamide reduced luciferase signal in all tissues. Our model demonstrates that
androgens can act in these tissues directly via AR, rather than exclusively via androgen aromatisation to estrogens
and activation of the estrogen receptor. Additionally, it visually demonstrates the fundamental importance of AR
signalling outside the normal role in the reproductive organs. This model represents an important tool for
physiological and developmental analysis of androgen signalling, and for characterization of known and novel
androgenic or antiandrogenic compounds.
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Introduction
Androgens are responsible for masculinization of male body
tissues, e.g. development of the internal and external genitalia,
and in both sexes, the androgen surge at puberty drives
development of secondary sexual characteristics, e.g.
increased skeletal muscle bulk, voice deepening, and axillary
and pubic hair growth [1]. The principal circulating androgen is
testosterone, most of which is synthesised from androgenic
precursors in the gonads. Less potent androgens (such as
dehydroepiandrosterone) are also produced by the adrenal
glands, and some peripheral conversion of adrenal androgens
to testosterone also occurs (more significantly in females).
Androgens act via the androgen receptor (AR), a ligand-
activated transcription factor which has structural homology to
the glucocorticoid receptor (GR), progesterone receptor (PR)
and mineralocorticoid receptor (MR), and to a lesser extent the
estrogen receptor (ERα).
Normal male physiological development requires a controlled
pattern of gene expression from fertilisation to gestation, and
involves expression of the SRY transcription factor (Sex-
determining Region Y) from the Y chromosome to initiate
phenotypic male sexual differentiation and testis development
[2–4]. These early testes secrete testosterone, which drives
differentiation and growth of the genital tissues and Wolffian
structures, while metabolism to the more potent agonist
dihydrotestosterone (DHT) by 5alpha-reductase enzymes in
target cells drives growth of the prostate and phallus. Reduced
androgen signalling in males can result in undervirilization and
infertility, while increased androgen signalling is associated
with increased prostate cancer risk [5,6]. In the male mouse
brain, the sexually dimorphic regions express high levels of AR
and male development is believed to result from exposure to
testicular androgens – indeed it can be mimicked in females by
prenatal androgen exposure [7,8].
In the female, androgens are produced by the adrenal,
ovarian and adipose tissues but circulate at a lower level than
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in the male. A key function of androgens in females is
aromatisation to estrogens, but the AR is expressed in several
female tissues, e.g. mammary gland, uterus, vulvar epithelium,
vaginal mucosa and in ovarian follicles where it maintains
follicle health during ovulation [9–12]. In the female brain,
androgens regulate initiation of sexual activity, libido and
mating behaviour [13,14]. Testosterone importance in the
female is demonstrated by profound effects of testosterone
insufficiency in menopausal or post-oophorectomied females,
including diminished libido, fatigue, hair loss, osteopenia,
osteoporosis and decreased body mass [15,16].
AR function and localization may be assessed by
immunohistochemistry or binding of radioactive ligands [17],
but such studies involve tissue analysis and the sacrifice of
many animals, and cannot determine the final level of AR
activity since each tissue expresses a repertoire of transcription
factors and coactivators that act along with the AR, resulting in
tissue-specific target gene expression. We have developed an
improved transgenic model for AR activity utilising firefly
luciferase as a reporter gene, allowing in vivo imaging in live
anaesthetized animals. Luciferase (Luc2P), being non-
mammalian, gives very low background signal and has been
engineered to contain degradation signals (hPEST) for rapid
protein turnover, allowing real-time signal responses to
changes in gene activation. Furthermore, consecutive
longitudinal images can be taken using the same animal.
The consensus response element for the AR is identical to
that of the closely related GR, PR and MR - a hexameric
bipartite binding site, comprising of an inverted repeat of
TGTTCT with a three nucleotide spacer - and therefore could
not be used due to lack of discrimination [18]. However,
promoter/enhancer analysis of androgen-responsive genes has
revealed additional non-consensus response elements with
apparent AR specificity. Two well-studied examples are the rat
dorsal prostate-specific probasin (PB) and the prostate trans-
epithelial transporter of IgM (secretory component or SC1.2)
genes [19–22]. These specific AREs differ from the inverted
repeat, having greater similarity to a direct repeat of the same
sequence but with a change of T-G in the first base - increasing
AR specificity while excluding cross-talk with other steroid
receptors [23,24]. Our reporter was constructed by cloning the
SC1.2-ARE upstream of a minimal thymidine kinase promoter,
containing a TATA box for RNA polymerase binding. We
excluded adjacent endogenous DNA sequences in order to rule
out binding of other transcription factors that could render the
response tissue-specific, as seen for prostate specific antigen
(PSA) gene promoter-reporter fusions [25]. Additionally,
targeted genome integration of our reporter gene eliminated
deleterious effects of random integration such as
heterochromatin-induced gene silencing. Further, the reporter
is activated by endogenous AR protein, thus will recapitulate
the endogenous androgen responses.
Results
Generation of a highly specific androgen reporter
luciferase construct
Our aim was to create a reporter construct that responds
specifically to active AR, with minimal crosstalk with other
steroids/steroid receptors. Activity was tested initially by
transient transfection into steroid receptor negative COS-1 cells
alongside vectors expressing human AR, GR, ERα, and PR,
and also in cells expressing one or two endogenous receptors.
The SC1.2-ARE was used as, of several tested, it showed the
greatest androgen induction and specificity for AR without
activation by other transfected or endogenous steroid
receptors, within the physiological range of steroid hormones
(see Dart et al., 2009 supplemental data) [26]. The SC1.2-ARE
sequence was cloned upstream of a minimal thymidine kinase
(tk) promoter to drive luciferase (luc2P) gene expression
(Figure 1A). Subsequently the construct was stably integrated
into cell lines known to endogenously express steroid receptors
(Figure 1B & C) - LNCaP cells (AR+), MCF-7 cells (ERα+/PR
+/AR+) and Du145 cells (AR-/GR+), and treated with the cognate
ligands. LNCaP/Luc cells showed good induction of the
reporter when treated with mibolerone, and dose-dependent
response to a broad range of different androgens, with no
significant response to estrogen (E2), progesterone (P4) or
dexamethasone (Dex) (Figure 1D). MCF-7/Luc cells showed
good androgen-induced luciferase responsiveness but were
devoid of any significant luciferase responses to E2 or P4
(Figure 1E). In the case of P4, this was seen even when cells
were pretreated with E2 to induce PR expression (Figure 1C &
E). Also in MCF-7/Luc cells, siRNA against the AR resulted in a
reduced level of AR transcripts as expected and concurrently
reduced the luciferase expression in the presence of androgen
(Figure 1F). No luciferase response was seen in dex-treated
Du145/Luc cells (Figure 1G, left hand side), but upon
transfection with an AR-expressing vector, an androgen-
induced response was seen, confirming the reporter was
functional (Figure 1G, right hand side). In summary, this
luciferase reporter responds specifically to AR activation in a
range of cell lines.
Luciferase expression in transgenic mice
The S.C. 1.2 ARE luciferase vector was used to generate
transgenic ARE-Luc mice (details in methods and
supplemental data Figure S1). First, we investigated AR
transcriptional activity as measured by luciferase activity in
adult male and female mice of approximately 6-10 weeks of
age. ARE-Luc mice, along with wild type controls, were injected
with luciferin substrate (150 mg/kg subcutaneous (s.c.)) and
imaged to detect bioluminescence. Male ARE-Luc mice
showed significant bioluminescence/photon emission observed
in body areas corresponding to the reproductive organs (Figure
2A). Minimal light emission was seen from the skin and limbs
of the male mice. Female ARE-Luc mice showed distinct
differences to the males, with bioluminescence from regions
corresponding to the mammary glands, multiple abdominal
signals and regions of skin. Overall total body bioluminescence
was approx. three times stronger in males than females. Wild
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Figure 1.  Analysis of the androgen receptor reporter construct in stably transfected cells.  (A) Schematic representation of
the ARE-tk-Luc androgen receptor reporter construct (hP = hPEST degradation signal). (B) Western blot analysis of steroid receptor
expression in MCF-7, LNCaP and Du145 cells growing in full media. (C) Western blot analysis of PR expression in hormone starved
MCF-7 cells -/+ E2 treatment for 24hr. (D), Luciferase activity from hormone treated LNCaP/Luc cells – treated for 24hours with
0-10nM mibolerone (Mib), estrogen (E2), progesterone (P4) and dexamethasone (Dex) (left hand side) and with 0-100nM of the
androgens - (Mib), dihydrotestosterone (DHT), testosterone (Tes), androstenedione (A-dione) and dehydroepiandrosterone (DHEA)
for 24 hours (right hand side). (E) Luciferase activity from hormone treated MCF-7/Luc cells – treated for 24hours with 0-10nM Mib,
E2 or P4 or with additional 24hr pre-treatment with E2 (10nM) to induce PR expression. (F) Q-PCR quantification of relative
expression of the steroid receptors AR, ER, and PR and luciferase transcripts in MCF-7/Luc cells, grown in full medium, transfected
with siRNA against androgen receptor. (F) Luciferase activity from Du145/Luc cells treated with 0-100nM dex or mib (left hand side)
or pre-transfected with an additional AR or empty vector expression constructs (right hand side). **P<0.01, *P<0.05 (t-test analysis).
doi: 10.1371/journal.pone.0071694.g001
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type mice showed no bioluminescence as expected (Figure 2A,
lower panel).
Intra peritoneal (i.p.) injection showed faster kinetics of
luciferin light emission, reaching steady state maximum around
5 minutes, compared to 10 minutes for the s.c. route (Figure
S2). However, the s.c. route was utilised to avoid signal bias
towards gonadal tissue adjacent to the i.p. site. The luciferase
signal remained stable for over 20 minutes post injection.
Androgen receptor activity in specific mouse tissues
Luciferase activity (normalised to protein content) was
measured from lysates of several different tissues from male
and female ARE-Luc mice aged 6-10 weeks. In male mice, the
tissues exhibiting highest luciferase activity/mg protein content
were the brain and the testes. The intestines, prostate, spleen,
and eye showed a modest luciferase activity and of the tissues
measured the lowest activity in males was seen in the
stomach, heart and lung (Figure 2B, upper panel).
In female mice, the strongest luciferase activity/mg protein
signal was seen in the intestines (omentum included), skin,
brain, bladder and spleen. Modest luciferase activity was seen
in the uterus, bone, gonadal fat pads, and ovaries (Figure 2B,
lower panel). Again, the lowest activity was seen in the heart
and lung, as well as liver.
Tissues were dissected out and imaged ex vivo 10 minutes
after luciferin injection. In male ARE-Luc mice, the testes,
prostate and the seminal vesicles accounted for the majority of
the light emitted from live male mice (Figure 3A, upper panel)
– the brain signal being masked by the skull until excised.
Moderate luciferase activity was also seen in the spleen, areas
of the brain, bone/bone marrow and omentum attached to the
intestine. Weaker but detectable AR-mediated luciferase
activity was also seen in the liver, perigonadal fat deposits and
specific regions of the heart (atrial region/vascular bundle).
In female mice, ex vivo imaging of tissues revealed strong
luciferase signal in the ovaries and the uterine horn, spleen and
large tracts of the omentum attached to the intestine (Figure
3A, lower panel). Moderate activity was seen in the brain,
bone and perigonadal and inguinal fat deposits.
In the brain of both sexes strong AR activity was detected in
specific regions of the brain upon coronal dissection, including
the cerebral cortex, thalamus and pituitary gland (Figure 3B&
C).
Reporter activity is maintained in cultured primary cells
Primary ARE-Luc mouse cells were cultured from various
tissues, and their steroid receptor and luciferase reporter gene
expression were analysed further. Pre-adipocyte cells
expressing AR, GR, ERα/β and PR (as analysed by
quantitative PCR Figure S3A), were starved for 48hours and
treated with various steroid hormones. Luciferase expression
was induced by androgen treatment, specifically mibolerone,
testosterone and to a lesser extent with androstenedione
(Figure S3B). Neither dexamethasone nor progesterone
induced luciferase activity in these cells, although GR and PR
expression predominate. Primary cells derived from the
salivary glands, uterus and the liver also produced varying
amounts of luciferase activity in culture when treated with
mibolerone (Figure S3C).
Androgen induced luciferase activity is inhibited by
anti-androgen bicalutamide
To further demonstrate that luciferase expression is
mediated by the AR, intact male ARE-Luc mice (aged 6-12
weeks) were treated with 50mg/kg/day of the antiandrogen
bicalutamide, in DMSO: propylene glycol (50:50), for 48hrs.
Mice were imaged at 24 and 48 hours and compared to vehicle
treated controls. Bicalutamide treatment reduced luciferase
expression in the gonadal region of the ARE-Luc mice at 24hrs
and significantly so at 48hrs (Figure 4A& B). Ex vivo organ
imaging revealed that bioluminescence was visibly reduced in
all tissues after 48hr bicalutamide treatment (Figure 4C,
compared to Figure 3A). Bioluminescence in intestine, heart
and bone was barely detectable, while the prostate and testes
showed, respectively, approximately 80 and 90% reduction
(Figure 4D).
Females showed a similar reduction of luciferase activity
when treated with 50mg/kg bicalutamide. Overall, whole body
luciferase signal was strongly reduced after 48 hours, and
specifically the combined abdominal and mammary gland
signal was reduced approximately 70% (Figure 5A& B). Ex
vivo imaging of the organs confirmed that bioluminescence had
dropped significantly in the intestine, ovary, and uterus (Figure
5C& D, and compare to Figure 3A).
Luciferase expression in tissues from ARE-Luc mice
correlates with AR expression
To confirm that luciferase is expressed in the AR-positive cell
types, a selection of the strongly AR expressing tissues were
also immunostained for luciferase expression. Adjacent
sections of tissues from ARE-Luc mice were stained with
antibodies against AR and luciferase. AR immunoreactivity was
detected in the nuclei of prostate, epididymal and seminal
vesicle epithelial cells in the male, as well as in distinct cell
layers of the cerebral cortex (Figure 6A). In the female, AR
immunoreactivity was detected in the nuclei of ovarian follicles
(granulosa cells), oviduct epithelial cells, salivary glands, and
uterine epithelial cells (Figure 6B). Cytoplasmic staining for
luciferase was seen in the same cell types and cell layers as
nuclear AR staining (Figure 6A& B).
Tissues expressing AR correlated with those demonstrating
luciferase activity (Figures 2B and 3), e.g. brain, testes,
prostate, ovaries, uterus and mammary glands. Certain tissues
did not show a close correlation e.g. AR levels were high in the
salivary glands, but luciferase activity was relatively low (see
Figures 2B and 6). Tissues such as the omentum and the eye
(and associated lacrimal glands) showed modest AR staining
(Figure 7) but relatively robust luciferase activity (Figure 2B).
Presently we do not know the mechanism behind such
differences; they may be due to local androgen levels, and/or
local co-activator/co-repressor ratios within tissues. However,
importantly, no luciferase activity was detected in tissues
without AR expression.
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Figure 2.  Androgen receptor reporter activity in transgenic mice.  (A), Bioluminescent imaging of male and female ARE-Luc
and C57/Bl/6J wild type mice, injected with 150mg/kg luciferin substrate, and imaged with a CCCD camera after 10 minutes. Figure
represents a greyscale photograph overlaid with a pseudocolour representation of bioluminescence; scale represents
photons/sec/cm2.
(B), Luciferase enzymatic assays from tissue homogenates taken from ARE-Luc mice, normalised to protein content (Bradford
assay). Male mice upper panel, female mice lower panel.
doi: 10.1371/journal.pone.0071694.g002
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Figure 3.  Bioluminescence analysis of ex vivo tissues.  Ex vivo bioluminescence imaging of tissues taken from ARE-Luc mice
injected with 150mg/kg luciferin substrate and killed and dissected after 10 minutes. (A), Images of male tissues (upper panel) and
female mice (lower panel). (B), Images of coronal sections through the cerebral cortex of a male and female mouse brain. CC -
Cerebral Cortex, Th - Thalamus, Hth - Hypothalamus. (c), Image of the underside of the male brain, showing pituitary and optic
nerve bundles. Figure represents a greyscale photograph overlaid with a pseudocolour representation of bioluminescence. Images
are representative of the pattern seen in several mice.
doi: 10.1371/journal.pone.0071694.g003
ARE-Luc Model of In Vivo AR Activity
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Figure 4.  Bicalutamide treatment reduces androgen receptor activity in male mice.  Bioluminescent imaging of male mice
treated with bicalutamide (50mg/kg) for 24 and 48 hours. (A), Graph indicates measured bioluminescence signal from the gonadal
region at the indicated timepoints; error bars represent the standard error from three mice in each group. (B), representative
bioluminescent image of vehicle and bicalutamide treated mice at 48hours. Figure represents a greyscale photograph overlaid with
a pseudocolour representation of bioluminescence; scale represents photons/sec/cm2. (C), panel showing ex vivo imaging of the
organs from bicalutamide treated mice after 48hours (intestines image not to scale). (D), Bioluminescence signal from the testes
and the prostate taken ex vivo, from male mice treated for 48hours with vehicle or bicalutamide. Error bars represent the standard
error from three mice. **P<0.01, *P<0.05 (t-test analysis).
doi: 10.1371/journal.pone.0071694.g004
ARE-Luc Model of In Vivo AR Activity
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Figure 5.  Bicalutamide treatment reduces androgen receptor activity in female mice.  (A), Bioluminescent imaging of female
mice treated with bicalutamide (50mg/kg) for 24 and 48 hours. Graph indicates measured bioluminescence signal from the
abdominal region at the indicated timepoints, error bars represent the standard error from three mice. (B), representative
bioluminescent image of vehicle and bicalutamide treated mice at 48hours. Figure represents a greyscale photograph overlaid with
a pseudocolour representation of bioluminescence; scale represents photons/sec/cm2. (C), panel showing ex vivo imaging of the
organs from bicalutamide treated mice after 48hours (intestines image not to scale). (D), Bioluminescence signal from the ovaries
and the intestines taken ex vivo, from female mice treated for 48hours with vehicle or bicalutamide. Error bars represent the
standard error from three mice, **P<0.01, *P<0.05 (t-test analysis).
doi: 10.1371/journal.pone.0071694.g005
ARE-Luc Model of In Vivo AR Activity
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Figure 6.  Analysis of AR and luciferase expression within a sample of mouse tissues.  (A), Immunohistochemical co-
localisation staining for AR (nuclear and cytoplasmic_ and luciferase (cytoplasmic) on consecutive formalin-fixed tissue sections
taken from the ARE-Luc male mice. Upper panel represents image at 10x magnification, with box inset and lower panel showing
40x magnification. (B), Immunohistochemical staining for AR in a variety of female mouse tissues.
doi: 10.1371/journal.pone.0071694.g006
ARE-Luc Model of In Vivo AR Activity
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Figure 7.  Upper panel - Mouse tissues: A, prostate; B, testis; C, thymus; D, brain; E, skin and hair follicle; F, kidney; G,
liver; H, uterus; I, intestine; J, spleen; K, colon; L, lacrimal gland; M, salivary gland; N, bone marrow; O, eye; P,
heart.  Lower panel - Human tissue: A, prostate; B, testis; C, thymus; D, brain; E, skin; F, kidney; G, liver; H, uterus; I, intestine; J,
spleen; K, colon; L, breast; M, intestine and omentum; N, bone marrow; O, ovary and follicle; P, lung.
doi: 10.1371/journal.pone.0071694.g007
ARE-Luc Model of In Vivo AR Activity
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AR expression patterns are similar in mouse and
human tissues
Formalin-fixed wild-type mouse tissue sections as well as a
multiple organ human normal tissue microarray were stained
for AR (Figure 7A& B). Mouse tissues positive for AR
expression showed very similar staining patterns to the
respective human tissue (Table 1). We did not take into
account any gross morphological differences in tissue –
especially relevant for the brain and prostate.
Discussion
The ARE-Luc mouse: a model for AR activity
AR drives transcriptional networks in varied tissue types and
is responsible for the development, maintenance and function
of several tissues in the body. However, relatively few
androgen-regulated genes have been well characterised, most
driving functions of the prostate e.g. those encoding kallikrein
enzymes (PSA and KLK2) and, in rodents, probasin (PB).
There is a need for models to study steroid receptor activity in
physiological settings and the first mouse model allowing
visualisation of endogenous steroid receptor activity was
developed for the ER by Maggi and co-workers [27,28]. To
develop a similar model for AR, it was necessary to circumvent
the issue that, unlike ER, AR binds a common response
element shared by several other steroid receptors. Our ARE-
Luc model utilizes an ARE that has been extensively tested in
vitro to minimise cross talk with other steroid receptors, with
specific emphasis on optimising the ARE type to exclude GR
binding and activation. In a previous model, the AR activity
indicator (ARAI) mouse, steroid receptor crosstalk is avoided
by expressing an engineered AR, in which the native DNA-
binding domain (DBD) is replaced by the Gal4-DBD, and a
Gal4-responsive luciferase reporter is used [29]. This study
showed lower AR activity than expected, possibly due to lack of
appropriate interaction domains required for maximal AR
activity [30,31]. The DBD is instrumental in driving the
androgen-specific genome response, as evidenced by altered
genomic responses in a model with the AR DBD replaced by
that of the GR (the SPARKI mouse) [32], and suggests a non-
native DBD could well influence the downstream response to
AR activation and representative AR responses will depend
upon the presence of intact AR.
The single SC1.2 ARE was weaker than PSA regulatory
AREs, but unlike these it did not show significant response to
GR [22,26]. Further, the exclusion of adjacent sequences that
contain binding sites for other transcription factors eliminates
the potential for tissue specific expression – the opposite
strategy was used in previous transgenic models that were
designed to give prostate specific expression [25,33,34]. To
avoid positional effects due to random integration as seen for
other models, e.g. that using the ARE from Sex-limited protein
(Slp) gene enhancer [35], we used a knock-in strategy into a
non-silenced genomic locus (Hprt). The use of a highly active
luciferase (luc2P) coupled to degradation signals ensured
sufficient activity for rapid and robust detection, with
opportunity for rapid flux in response to changes in hormone
levels. We acknowledge that a plethora of transcription factors
and co-activator proteins may act in concert with the AR to fine-
tune activation but no one model could reproduce this level of
Table 1. Summary of the immunohistochemical analysis of
AR in mouse tissue sections, and human normal tissue
microarray.
Tissue Staining pattern
Intensity
mouse
Intensity
human
Adipose tissue Weak staining, nuclear + +
Bladder wall Occasional nuclei in stromalcells + NA
Bone marrow Strong nuclear, 50% of cells +++ ++
Brain
Strong nuclear, multiple
neuronal cell types, highly
regional
++ ++
Caecum Weak nuclear + +
Colon Mixed cytoplasmic andnuclear staining. + +
Epididymis Nuclear and cytoplasmic inluminal epithelial cells +++ NA
Eye Weak nuclear on inner retinallayer + NA
Fallopian tube &
oviduct Strong nuclear stain +++ NA
Heart Cytoplasmic staining, areaspecific nuclear staining + NA
Kidney Weak cytoplasmic granular,nucleoli + ++
Liver Weak cytoplasmic + +
Lung Occasional positive nucleus + +
Muscle (leg) Very weak nuclear stain + +
Omentum Nuclear stain in some celllayers and tubules + +
Optic nerve-
associated
glands
Granular cytoplasmic, weak
nuclear + NA
Ovary Strong nuclear stain ingranulosa cells +++ ++
Prostate Nuclear in luminal epithelialcells ++++ ++++
Salivary gland Strong nuclear andcytoplasmic +++ NA
Seminal Vesicle Nuclear and cytoplasmic +++ ++
Skin
Nuclear staining in specific
epidermal layers and hair
follicles
++ ++
Small intestine Weak / cytoplasmic + +
Spleen Nuclear, also cytoplasmic infemale +++ +++
Stomach Cytoplasmic and nuclear instomach wall + ++
Testis Nuclear in Sertoli and Leydigcells ++ ++
Thymus Strong nuclear ++ ++
Uterus Strong nuclear stain in somelayers ++ ++
ARE-Luc Model of In Vivo AR Activity
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complexity, and therefore our model reports and assays the
activity of transcriptionally active AR.
AR activity in male and female ARE-Luc mice
Luciferase activity was seen only in those tissues expressing
AR, and the reporter was silent in tissues lacking AR, indicating
no constitutive activation or silencing due to positional
integration effects although it is impossible to completely rule
out “false negative” results due to the unlikely scenario of an as
yet undetected tissue specificity of the reporter minimised by
use of an artificial promoter containing a minimal ARE.
Importantly, a strong reduction in luciferase signal was seen
when AR was inhibited by bicalutamide – even though
androgens were still circulating in the intact animal –
demonstrating that the luciferase activity in these mice is
indeed mediated by the AR. Although the signal in the majority
of luciferase-expressing organs became almost undetectable in
both sexes following anti-androgen treatment, some residual
signal was seen in the most strongly positive organs e.g. the
testes. This is likely due to incomplete inhibition by the
competitive anti-androgen bicalutamide, as testes are known to
have the highest tissue testosterone concentrations [36]. A
more complete control to demonstrate the dependence on AR
activity would be to cross the mice with an AR-deficient mouse
such as the Tfm or ARKO model [8,37]; however, this is
problematic due to the X-chromosomal location of both the AR
gene and the Hprt locus into which the luciferase reporter is
inserted.
Ex vivo tissue examination showed exquisitely specific
localisation of luciferase activity, for example in the gonads and
brain (indicating the ability of luciferin substrate to cross the
blood brain barrier) in both sexes, which correlated well with
AR protein expression within tissues (In turn, sites of AR
expression in mouse correlated with expression in human
tissues). Within the brain, in both sexes, AR activity was highly
localised to specific regions, detailed study of which will be the
focus of future research. Several reports have suggested that
within the brain testosterone activity is mediated by ER after
aromatisation of testosterone, especially during foetal
development. Certain areas of the brain are more susceptible
to aromatisation and these areas adhere well to the theory, e.g.
the sexually dimorphic nucleus of the preoptic area and the
anteroventral periventricular nucleus [38]. However, AR has
been well documented to be present in the brains of both
males and females in mammals, with highly complex functions;
further, aromatisation does not account for all the sexual
differentiation in brain morphology and in animal behaviour
[39–41]. Complete androgen insensitivity syndrome (due to
lack of AR function) presents with a female habitus and
physiology, including the developmental brain pattern - in spite
of internalised testes that secrete normal levels of testosterone
[42]. This indicates a requirement for AR signalling in brain
masculinisation. Further, human males with aromatase
mutations present as male with a masculinised brain pattern,
indicating a limited role for ER [43]. We observed high AR
protein levels in certain regions of the brain via
immunohistochemistry, concomitant with luciferase staining
and strong luciferase activity in ex vivo tissue. Our model
supports the hypothesis that aromatisation is not the only
mechanism of androgen activity in the brain, and that AR is
transcriptionally active within certain brain regions. It is not
possible to state, at this stage, which androgen is mediating the
effect, but future crosses of ARE-Luc mice with a 5α-reductase
knockout mouse should clarify whether testosterone
(aromatisable) or DHT (non-aromatisable) is responsible.
Another regions showing high luciferase activity was the
gastric tract, notably the surrounding intestinal omentum. The
omentum represents a complex tissue that has multiple roles
including fat storage [44,45] and immunological responses
[46,47] – both roles with a strong androgen stimulus (e.g.
spleen, bone marrow, thymus and adipose tissue all show
robust AR and luciferase activity). There are contradictory
reports of AR expression in the colon. Although we saw low to
moderate staining for AR and luciferase in the small intestine
and colonic surfaces, including the villi, proteinatlas.org and
other reports indicated no staining for AR in these tissues
[48,49]. However, others have found AR expression in several
compartments of the mammalian intestine [50] and have
indicated a role for AR in the intestine in modulating ion
channels, glucose and calcium uptake [51–54]. Interestingly,
androgens also affect smooth muscle activity in contractile
peristalsis [55],. Our staining is consistent with this since we
see AR positivity in surrounding muscle as well as the intestine
itself, hence the luciferase signal observed could be from a
combination of these. The role of androgens in intestinal/
omentum activity requires further analysis.
This study shows that the AR is indeed very active outside its
well-defined role in reproductive tissues. We have observed AR
expression and activity in a variety of tissues in which the role
of steroid hormones are poorly understood. The retina and
choroid cells of the eye showed modest AR expression and
luciferase activity, as did the lacrimal glands – tissues known to
express sex steroid receptors [56,57]. Strong AR expression
and activity was seen in the immunological system, including
the bone marrow, spleen and thymus. AR expression in the
spleen is somewhat controversial, for instance
immunohistochemical staining for AR in all mouse tissues by
Takeda et al. did not not show reactivity [58]. However, more
recent studies have shown modest levels of AR expression and
an important role for testosterone in the functioning of the
immune system, for instance splenic B cells express AR in
mice, as do leukocytes from both spleen and thymus in rats
[59,60]. The AR activity seen by luciferase imaging is thus
likely to be due to the immune cell contents of the spleen and
indeed AR immunoreactivity is not uniform across the spleen
tissue (Figure 7). Interesting, sex differences have been
observed in a number of models of autoimmune diseases,
reflecting the well-known gender bias in humans. Androgens
tend to have a suppressive effect upon the immune system,
and castration (or lack of transcriptionally active functional AR)
increases lymphocyte numbers in both thymus and spleen
[37,61–63]. Tissues such as the heart and the brain showed
highly regional activity and expression both within the tissue
itself and exhibited differences between the sexes. The model
shows clearly that androgens have a plethora of effects in
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males as expected, but also demonstrates the importance of
this signalling pathway in females.
In summary, we report a highly specific model for imaging
endogenous AR activity in mice that overcomes previous
limitations including crosstalk with other receptors, random
integration, non-endogenous AR and tissue-specific
expression. Our model shows that androgens have a wide
range of target tissues, both in males and females, outside the
most widely-studied reproductive tract. The data shown here
represent a snapshot of the AR activity within adult mice (6-10
weeks), thus exclude any dramatic changes predicted during
development and puberty, as well as effects of hormonal
fluctuations during the female estrous cycle and less dramatic
changes during aging. As well as such developmental studies,
future uses of this model include evaluation and detection
androgenic xenobiotics and selective androgen receptor
modulators (SARMs) with the aim of producing tissue-selective
antagonistic or agonistic effects in diseases such as breast and
prostate cancer, polycystic ovarian syndrome and hyper- and
hypogonadism [64].
Materials and Methods
Ethics statement
All mouse procedures were performed in accordance with
the UK Animals (Scientific Procedures) Act 1986 under Home
Office license.
Reporter construction
A 168 bp fragment containing the minimal thymidine kinase
(tk) promoter from the herpes simplex virus was cloned into the
Sac1/Xho1 site of pGL4.18 (Promega) to generate p-tk-Luc.
DNA oligomers (EurofinsMWG, Germany) coding for the SC1.2
ARE sequence (GGCTCTttcAGTTCT) were ligated into the
Sac1/Xba1 site of p-tk-Luc to generate p-tk-Luc-ARE (Figure
1A). This construct was tested for androgen specificity and
inducibility, see Dart et al. 2009 and supplemental data therein.
Transgenic mice
The S.C. 1.2 ARE-Luc knock-in (ARE-Luc) mouse was
generated in collaboration with GenOway (Lyon, France). The
p-tk-Luc-ARE was cloned into the CBE1-HR Hypoxanthine
phosphoribosyltransferase gene (Hprt) conditional targeting
vector, containing the Hprt promoter and exon 1. This gene-
targeting construct was introduced into male mouse embryonic
stem (E14Tg2a ES) cells of the 129P2/OlaHsd strain in which
the 35kb of the Hprt gene, encompassing the 5’ UTR up to
intron 2, is deleted. The targeting construct then integrated into
the X-chromosome by homologous recombination (Figure
S1A). ES cells were selected using HAT medium
(Hypoxanthine, Aminopterin and Thymidine). Homologous
recombination was confirmed by Southern blotting (Figure
S1B). The modified ES cells were inserted into C57BL/6J
blastocysts, which were then implanted into the uterus of OF1
pseudo-pregnant female mice to generate chimeric offspring.
The chimeric males were crossed with C57BL/6J strain wild-
type females to generate F1 mice (Figure S1C), from which the
heterozygous females were used for breeding with wild-type
C57BL/6J males to generate hemizygous males and
heterozygous females (Figure S1D). Homozygous females
were produced at the following generation by back-crossing
(Figure S1E). All offspring were genotyped by PCR of genomic
DNA extracted from ear notching.
Luciferase assay
Tissue was pulverized by grinding in liquid nitrogen and then
completely homogenised, using a microfuge pestle, in reporter
lysis buffer with protease inhibitors (Promega). Lysate (20µl)
was mixed with luciferin substrate (20µl) and light emission
measured using the Steadylite luciferase assay kit
(PerkinElmer, U.K.) in a Topcount luminometer (Packard
Instrument Co, USA). Light expression was then normalised to
protein content as measured by Bradford Assay.
Luciferase imaging
Anaesthetized mice (3% isofluorane with O2 carrier, Abbott
Animal Health UK) were injected i.p. or s.c. with D-luciferin
(Caliper Life Sciences Ltd, Runcorn, UK) at 150 mg/kg, 10 min
before imaging. Light emission from luciferase was detected by
the IVIS Imaging System 100 series (Xenogen Corporation),
and overlaid as a pseudocolour image with reference scale,
upon a greyscale optical image.
For ex vivo imaging, mice were sacrificed 10 min after
luciferin injection, and immediately dissected. Target organ was
rinsed briefly in PBS and placed under the bioluminescent
camera.
Histology and immunohistochemistry
Standard protocols were carried out as described [65].
Antibodies used were: AR (N-20 Santa Cruz) @1:300, and
Luciferase (Promega). The Vectastain avidin–biotin complex
(Vector Labs, Peterborough, U.K.) was used for detection,
using diaminobenzidine chromogenic substrate. Negative
controls lacking primary antibody were also carried out. Digital
images were captured using E1000 microscope (Nikon,
Kingston upon Thames, UK) and Eclipse Net image analysis
software.
Additional Information
The ARE-luc mouse line will be made available for non-profit
research use: for details please contact the corresponding
author Dr C. L. Bevan.
Supporting Information
Figure S1.  Southern blot validation of the 5’ and 3’
homologous recombination event. A, Schematic
representation of the wild type, deleted and the recombined
Hprt allele with the relevant restriction sites for the Southern
blot analysis shown. Black lines represent the homology arms.
The Southern blot strategy for the detection of the 5’ and 3’
targeting events is indicated by arrows. B and C, Southern blot
analysis of genomic DNA of the tested ES clones and the wild-
type C57Bl/6 Hprt allele probed with 5’ probe D and 3’ probe
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A.D, validation of the F1 generation, and E, validation of the N2
generation.
(TIF)
Figure S2.  Luciferase kinetics depends on route of
injection. Comparison of the time kinetics of bioluminescent
signal from ARE-Luc mice injected with 150mg/kg luciferin
substrate via either the i.p. or s.c. route.
(TIF)
Figure S3.   Analysis of luciferase activity and expression
in mouse ARE-Luc primary cells in culture. A, Relative
mRNA expression of steroid hormone receptors in gonadal pre-
adipocytes. B, Luciferase activity in gonadal adipose cells
grown under conditions of hormone starvation for 72 hours and
treated with 10nM hormone for 24 hours. C, Luciferase
expression in various primary cell types, hormone-starved for
72 hours and treated with mibolerone (10nM) or equivalent
volume vehicle (Eth) for 24 hours.
(TIF)
Methods S1.  Further details are provided for Cell culture,
Primary Cell Culture, Genomic DNA extraction and PCR, RNA
extraction, RT-PCR and Southern Blotting in the Supporting
Information for this paper.
(DOCX)
Acknowledgements
We are grateful to Drs James Turton, Mark Fenwick and Bobbi
Fleiss (Institute of Reproductive and Developmental Biology,
Imperial College London) for their technical assistance and
advice, Prof. Malcolm Parker and all members of the Androgen
Signalling Laboratory for continued advice and discussion, and
Profs Lee Smith, Philippa Saunders and Frank Claessens for
useful discussion.
Author Contributions
Conceived and designed the experiments: CB AD EA JW.
Performed the experiments: AD. Analyzed the data: AD CB.
Contributed reagents/materials/analysis tools: CB AD EA.
Wrote the manuscript: CB AD JW EA. Revised the manuscript:
CB AD.
References
1. Brinkmann AO (2011) Molecular mechanisms of androgen action--a
historical perspective. Methods Mol Biol 776: 3-24. doi:
10.1007/978-1-61779-243-4_1. PubMed: 21796517.
2. Hacker A, Capel B, Goodfellow P, Lovell-Badge R (1995) Expression of
Sry, the mouse sex determining gene. Development 121: 1603-1614.
PubMed: 7600978.
3. Sekido R, Bar I, Narváez V, Penny G, Lovell-Badge R (2004) SOX9 is
up-regulated by the transient expression of SRY specifically in Sertoli
cell precursors. Dev Biol 274: 271-279. doi:10.1016/j.ydbio.
2004.07.011. PubMed: 15385158.
4. Sekido R (2010) SRY: A transcriptional activator of mammalian testis
determination. Int J Biochem Cell Biol 42: 417-420. doi:10.1016/j.biocel.
2009.12.005. PubMed: 20005972.
5. Feldman SR (1992) Androgen insensitivity syndrome (testicular
feminization): a model for understanding steroid hormone receptors. J
Am Acad Dermatol 27: 615-619
6. Jenster G (1999) The role of the androgen receptor in the development
and progression of prostate cancer. Semin Oncol 26: 407-421.
PubMed: 10482183.
7. Goldstein JM, Seidman LJ, Horton NJ, Makris N, Kennedy DN et al.
(2001) Normal sexual dimorphism of the adult human brain assessed
by in vivo magnetic resonance imaging. Cereb Cortex 11: 490-497. doi:
10.1093/cercor/11.6.490. PubMed: 11375910.
8. Sato T, Matsumoto T, Kawano H, Watanabe T, Uematsu Y et al. (2004)
Brain masculinization requires androgen receptor function. Proc Natl
Acad Sci U S A 101: 1673-1678. doi:10.1073/pnas.0305303101.
PubMed: 14747651.
9. Sen A, Hammes SR (2010) Granulosa cell-specific androgen receptors
are critical regulators of ovarian development and function. Mol
Endocrinol 24: 1393-1403. doi:10.1210/me.2010-0006. PubMed:
20501640.
10. Berman JR, Almeida FG, Jolin J, Raz S, Chaudhuri G et al. (2003)
Correlation of androgen receptors, aromatase, and 5-alpha reductase
in the human vagina with menopausal status. Fertil Steril 79: 925-931.
doi:10.1016/S0015-0282(02)04923-3. PubMed: 12749432.
11. Hodgins MB, Spike RC, Mackie RM, MacLean AB (1998) An
immunohistochemical study of androgen, oestrogen and progesterone
receptors in the vulva and vagina. Br J Obstet Gynaecol 105: 216-222.
doi:10.1111/j.1471-0528.1998.tb10056.x. PubMed: 9501790.
12. Shiina H, Matsumoto T, Sato T, Igarashi K, Miyamoto J et al. (2006)
Premature ovarian failure in androgen receptor-deficient mice. Proc
Natl Acad Sci U S A 103: 224-229. doi:10.1073/pnas.0506736102.
PubMed: 16373508.
13. Ogawa S, Chan J, Chester AE, Gustafsson JA, Korach KS et al. (1999)
Survival of reproductive behaviors in estrogen receptor beta gene-
deficient (betaERKO) male and female mice. Proc Natl Acad Sci U S A
96: 12887-12892. doi:10.1073/pnas.96.22.12887. PubMed: 10536018.
14. Davis SR, Tran J (2001) Testosterone influences libido and well being
in women. Trends Endocrinol Metab 12: 33-37. doi:10.1016/
S1043-2760(00)00333-7. PubMed: 11137039.
15. Bachmann G, Bancroft J, Braunstein G, Burger H, Davis S et al. (2002)
Female androgen insufficiency: the Princeton consensus statement on
definition, classification, and assessment. Fertil Steril 77: 660-665. doi:
10.1016/S0015-0282(02)02969-2. PubMed: 11937111.
16. Braunstein GD (2002) Androgen insufficiency in women: summary of
critical issues. Fertil Steril 77 Suppl 4: S94-S99. doi:10.1016/
S0015-0282(02)02962-X. PubMed: 12007911.
17. Chang C, Saltzman A, Yeh S, Young W, Keller E et al. (1995)
Androgen receptor: an overview. Crit Rev Eukaryot Gene Expr 5:
97-125. doi:10.1615/CritRevEukarGeneExpr.v5.i2.10. PubMed:
8845584.
18. Beato M, Chalepakis G, Schauer M, Slater EP (1989) DNA regulatory
elements for steroid hormones. J Steroid Biochem 32: 737-747. doi:
10.1016/0022-4731(89)90521-9. PubMed: 2661921.
19. Dodd JG, Sheppard PC, Matusik RJ (1983) Characterization and
cloning of rat dorsal prostate mRNAs. Androgen regulation of two
closely related abundant mRNAs. J Biol Chem 258: 10731-10737.
PubMed: 6193116.
20. Mostov KE (1994) Transepithelial transport of immunoglobulins. Annu
Rev Immunol 12: 63-84. doi:10.1146/annurev.iy.12.040194.000431.
PubMed: 8011293.
21. Rennie PS, Bruchovsky N, Leco KJ, Sheppard PC, McQueen SA et al.
(1993) Characterization of two cis-acting DNA elements involved in the
androgen regulation of the probasin gene. Mol Endocrinol 7: 23-36. doi:
10.1210/me.7.1.23. PubMed: 8446105.
22. Verrijdt G, Schoenmakers E, Alen P, Haelens A, Peeters B et al. (1999)
Androgen specificity of a response unit upstream of the human
secretory component gene is mediated by differential receptor binding
to an essential androgen response element. Mol Endocrinol 13:
1558-1570. doi:10.1210/me.13.9.1558. PubMed: 10478846.
23. Schoenmakers E, Alen P, Verrijdt G, Peeters B, Verhoeven G et al.
(1999) Differential DNA binding by the androgen and glucocorticoid
receptors involves the second Zn-finger and a C-terminal extension of
the DNA-binding domains. Biochem J 341(3): 515-521. doi:
10.1042/0264-6021:3410515. PubMed: 10417312.
ARE-Luc Model of In Vivo AR Activity
PLOS ONE | www.plosone.org 14 August 2013 | Volume 8 | Issue 8 | e71694
24. Denayer S, Helsen C, Thorrez L, Haelens A, Claessens F (2010) The
rules of DNA recognition by the androgen receptor. Mol Endocrinol 24:
898-913. doi:10.1210/me.2009-0310. PubMed: 20304998.
25. Seethammagari MR, Xie X, Greenberg NM, Spencer DM (2006) EZC-
prostate models offer high sensitivity and specificity for noninvasive
imaging of prostate cancer progression and androgen receptor action.
Cancer Res 66: 6199-6209. doi:10.1158/0008-5472.CAN-05-3954.
PubMed: 16778194.
26. Dart DA, Spencer-Dene B, Gamble SC, Waxman J, Bevan CL (2009)
Manipulating prohibitin levels provides evidence for an in vivo role in
androgen regulation of prostate tumours. Endocr Relat Cancer 16:
1157-1169. doi:10.1677/ERC-09-0028. PubMed: 19635783.
27. Ciana P, Di Luccio G, Belcredito S, Pollio G, Vegeto E et al. (2001)
Engineering of a mouse for the in vivo profiling of estrogen receptor
activity. Mol Endocrinol 15: 1104-1113. doi:10.1210/me.15.7.1104.
PubMed: 11435611.
28. Ciana P, Raviscioni M, Mussi P, Vegeto E, Que I et al. (2003) In vivo
imaging of transcriptionally active estrogen receptors. Nat Med 9:
82-86. PubMed: 12483206.
29. Ye X, Han SJ, Tsai SY, DeMayo FJ, Xu J et al. (2005) Roles of steroid
receptor coactivator (SRC)-1 and transcriptional intermediary factor
(TIF) 2 in androgen receptor activity in mice. Proc Natl Acad Sci U S A
102: 9487-9492. doi:10.1073/pnas.0503577102. PubMed: 15983373.
30. He B, Kemppainen JA, Voegel JJ, Gronemeyer H, Wilson EM (1999)
Activation function 2 in the human androgen receptor ligand binding
domain mediates interdomain communication with the NH(2)-terminal
domain. J Biol Chem 274: 37219-37225. doi:10.1074/jbc.274.52.37219.
PubMed: 10601285.
31. Helsen C, Dubois V, Verfaillie A, Young J, Trekels M et al. (2012)
Evidence for DNA-binding domain--ligand-binding domain
communications in the androgen receptor. Mol Cell Biol 32: 3033-3043.
doi:10.1128/MCB.00151-12. PubMed: 22645304.
32. Schauwaers K, De Gendt K, Saunders PT, Atanassova N, Haelens A et
al. (2007) Loss of androgen receptor binding to selective androgen
response elements causes a reproductive phenotype in a knockin
mouse model. Proc Natl Acad Sci U S A 104: 4961-4966. doi:10.1073/
pnas.0610814104. PubMed: 17360365.
33. Lyons SK, Lim E, Clermont AO, Dusich J, Zhu L et al. (2006)
Noninvasive bioluminescence imaging of normal and spontaneously
transformed prostate tissue in mice. Cancer Res 66: 4701-4707. doi:
10.1158/0008-5472.CAN-05-3598. PubMed: 16651422.
34. Ellwood-Yen K, Wongvipat J, Sawyers C (2006) Transgenic mouse
model for rapid pharmacodynamic evaluation of antiandrogens. Cancer
Res 66: 10513-10516. doi:10.1158/0008-5472.CAN-06-1397. PubMed:
17079473.
35. Pihlajamaa P, Zhang FP, Saarinen L, Mikkonen L, Hautaniemi S et al.
(2011) The phytoestrogen genistein is a tissue-specific androgen
receptor modulator. Endocrinology 152: 4395-4405. doi:10.1210/en.
2011-0221. PubMed: 21878517.
36. Grad JM, Dai JL, Wu S, Burnstein KL (1999) Multiple androgen
response elements and a Myc consensus site in the androgen receptor
(AR) coding region are involved in androgen-mediated up-regulation of
AR messenger RNA. Mol Endocrinol 13: 1896-1911. doi:10.1210/me.
13.11.1896. PubMed: 10551783.
37. Charest NJ, Zhou ZX, Lubahn DB, Olsen KL, Wilson EM et al. (1991) A
frameshift mutation destabilizes androgen receptor messenger RNA in
the Tfm mouse. Mol Endocrinol 5: 573-581. doi:10.1210/mend-5-4-573.
PubMed: 1681426.
38. Zuloaga DG, Puts DA, Jordan CL, Breedlove SM (2008) The role of
androgen receptors in the masculinization of brain and behavior: what
we’ve learned from the testicular feminization mutation. Horm Behav
53: 613-626. doi:10.1016/j.yhbeh.2008.01.013. PubMed: 18374335.
39. Menard CS, Harlan RE (1993) Up-regulation of androgen receptor
immunoreactivity in the rat brain by androgenic-anabolic steroids. Brain
Res 622: 226-236. doi:10.1016/0006-8993(93)90823-6. PubMed:
8242360.
40. Wood RI, Newman SW (1999) Androgen receptor immunoreactivity in
the male and female Syrian hamster brain. J Neurobiol 39: 359-370.
doi:10.1002/(SICI)1097-4695(19990605)39:3. PubMed: 10363909.
41. Fernández-Guasti A, Kruijver FP, Fodor M, Swaab DF (2000) Sex
differences in the distribution of androgen receptors in the human
hypothalamus. J Comp Neurol 425: 422-435. doi:
10.1002/1096-9861(20000925)425:3. PubMed: 10972942.
42. Imperato-McGinley J, Gautier T, Cai LQ, Yee B, Epstein J et al. (1993)
The androgen control of sebum production. Studies of subjects with
dihydrotestosterone deficiency and complete androgen insensitivity. J
Clin Endocrinol Metab 76: 524-528. doi:10.1210/jc.76.2.524. PubMed:
8381804.
43. Grumbach MM, Auchus RJ (1999) Estrogen: consequences and
implications of human mutations in synthesis and action. J Clin
Endocrinol Metab 84: 4677-4694. doi:10.1210/jc.84.12.4677. PubMed:
10599737.
44. Demerath EW, Ritter KJ, Couch WA, Rogers NL, Moreno GM et al.
(2007) Validity of a new automated software program for visceral
adipose tissue estimation. Int J Obes (Lond) 31: 285-291. doi:10.1038/
sj.ijo.0803409.
45. Demerath EW, Sun SS, Rogers N, Lee M, Reed D et al. (2007)
Anatomical patterning of visceral adipose tissue: race, sex, and age
variation. Obesity (Silver Spring) 15: 2984-2993. doi:10.1038/oby.
2007.356. PubMed: 18198307.
46. Platell C, Cooper D, Papadimitriou JM, Hall JC (2000) The omentum.
World J Gastroenterol 6: 169-176. PubMed: 11819552.
47. Kantor AB, Herzenberg LA (1993) Origin of murine B cell lineages.
Annu Rev Immunol 11: 501-538. doi:10.1146/annurev.iy.
11.040193.002441. PubMed: 8476571.
48. Janssen PJ, Brinkmann AO, Boersma WJ, Van der Kwast TH (1994)
Immunohistochemical detection of the androgen receptor with
monoclonal antibody F39.4 in routinely processed, paraffin-embedded
human tissues after microwave pre-treatment. J Histochem Cytochem
42: 1169-1175. doi:10.1177/42.8.8027537. PubMed: 8027537.
49. Loda M, Fogt F, French FS, Posner M, Cukor B et al. (1994) Androgen
receptor immunohistochemistry on paraffin-embedded tissue. Mod
Pathol 7: 388-391. PubMed: 8058713.
50. Carriere RM (1966) The influence of thyroid and testicular hormones on
the epithelium of crypts of Lieberkühn in the rat’s intestine. Anat Rec
156: 423-431. doi:10.1002/ar.1091560406. PubMed: 5963414.
51. Sauerwein H, Pfaffl M, Hagen-Mann K, Malucelli A, Meyer HH (1995)
Expression of estrogen and androgen receptor in the bovine
gastrointestinal tract. Dtsch Tierarztl Wochenschr 102: 164-168.
PubMed: 7555698.
52. Pfaffl MW, Lange IG, Meyer HH (2003) The gastrointestinal tract as
target of steroid hormone action: quantification of steroid receptor
mRNA expression (AR, ERalpha, ERbeta and PR) in 10 bovine
gastrointestinal tract compartments by kinetic RT-PCR. J Steroid
Biochem Mol Biol 84: 159-166. doi:10.1016/S0960-0760(03)00025-6.
PubMed: 12710999.
53. Tuohimaa P, Niemi M (1968) The effect of testosterone on cell renewal
and mitotic cycles in sex accessory glands of castrated mice. Acta
Endocrinol (Copenh) 58: 696-704. PubMed: 5695786.
54. Carmena MJ, Recio MN, Prieto JC (1988) Influence of castration and
testosterone treatment on the vasoactive intestinal peptide receptor/
effector system in rat prostatic epithelial cells. Biochim Biophys Acta
969: 86-90. doi:10.1016/0167-4889(88)90091-2. PubMed: 2832001.
55. González-Montelongo MC, Marín R, Gómez T, Díaz M (2010)
Androgens are powerful non-genomic inducers of calcium sensitization
in visceral smooth muscle. Steroids 75: 533-538. doi:10.1016/j.steroids.
2009.09.012. PubMed: 19800357.
56. Wickham LA, Rocha EM, Gao J, Krenzer KL, da Silveira LA et al.
(1998) Identification and hormonal control of sex steroid receptors in
the eye. Adv Exp Med Biol 438: 95-100. doi:
10.1007/978-1-4615-5359-5_12. PubMed: 9634870.
57. Tachibana M, Kobayashi Y, Kasukabe T, Kawajiri K, Matsushima Y
(2000) Expression of androgen receptor in mouse eye tissues. Invest
Ophthalmol Vis Sci 41: 64-66. PubMed: 10634602.
58. Takeda H, Chodak G, Mutchnik S, Nakamoto T, Chang C (1990)
Immunohistochemical localization of androgen receptors with mono-
and polyclonal antibodies to androgen receptor. J Endocrinol 126:
17-25. doi:10.1677/joe.0.1260017. PubMed: 2199591.
59. Benten WP, Stephan C, Wunderlich F (2002) B cells express
intracellular but not surface receptors for testosterone and estradiol.
Steroids 67: 647-654. doi:10.1016/S0039-128X(02)00013-2. PubMed:
11996938.
60. Butts CL, Shukair SA, Duncan KM, Harris CW, Belyavskaya E et al.
(2007) Evaluation of steroid hormone receptor protein expression in
intact cells using flow cytometry. Nucl Recept Signal 5: e007. PubMed:
17710123.
61. Viselli SM, Stanziale S, Shults K, Kovacs WJ, Olsen NJ (1995)
Castration alters peripheral immune function in normal male mice.
Immunology 84: 337-342. PubMed: 7751013.
62. MacLean HE, Moore AJ, Sastra SA, Morris HA, Ghasem-Zadeh A et al.
(2010) DNA-binding-dependent androgen receptor signaling
contributes to gender differences and has physiological actions in
males and females. J Endocrinol 206: 93-103. doi:10.1677/
JOE-10-0026. PubMed: 20395380.
63. Ellis TM, Moser MT, Le PT, Flanigan RC, Kwon ED (2001) Alterations
in peripheral B cells and B cell progenitors following androgen ablation
ARE-Luc Model of In Vivo AR Activity
PLOS ONE | www.plosone.org 15 August 2013 | Volume 8 | Issue 8 | e71694
in mice. Int Immunol 13: 553-558. doi:10.1093/intimm/13.4.553.
PubMed: 11282994.
64. Narayanan R, Mohler ML, Bohl CE, Miller DD, Dalton JT (2008)
Selective androgen receptor modulators in preclinical and clinical
development. Nucl Recept Signal 6: e010. PubMed: 19079612.
65. Powell SM, Christiaens V, Voulgaraki D, Waxman J, Claessens F et al.
(2004) Mechanisms of androgen receptor signalling via steroid receptor
coactivator-1 in prostate. Endocr Relat Cancer 11: 117-130. doi:
10.1677/erc.0.0110117. PubMed: 15027889.
ARE-Luc Model of In Vivo AR Activity
PLOS ONE | www.plosone.org 16 August 2013 | Volume 8 | Issue 8 | e71694
